Literature DB >> 16670313

Targeting melanoma cells with human high molecular weight-melanoma associated antigen-specific antibodies elicited by a peptide mimotope: functional effects.

Wei Luo1, Eric Ko, Jeff Chi-feng Hsu, Xinhui Wang, Soldano Ferrone.   

Abstract

Human high molecular weight-melanoma associated Ag (HMW-MAA) mimics have been shown to elicit HMW-MAA-specific humoral immune responses that appear to be clinically beneficial. This finding has stimulated interest in characterizing the mechanism(s) underlying the ability of the elicited Abs to exert an anti-tumor effect. To address this question, in the present study, we have generated HMW-MAA-specific Abs by sequentially immunizing rabbits with the peptide P763.74, which mimics the HMW-MAA determinant recognized by mAb 763.74, and with HMW-MAA(+) melanoma cells. HMW-MAA-specific Abs isolated from immunized rabbits mediated cell-dependent cytotoxicity but did not mediate complement-dependent cytotoxicity of HMW-MAA(+) melanoma cells. These Abs also effectively inhibited spreading, migration and Matrigel invasion of HMW-MAA(+) melanoma cells. Besides contributing to our understanding of the role of HMW-MAA in the biology of melanoma cells, these results suggest that both immunological and nonimmunological mechanisms underlie the beneficial clinical effects associated with the induction of HMW-MAA-specific Abs in melanoma patients immunized with a HMW-MAA mimic.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16670313     DOI: 10.4049/jimmunol.176.10.6046

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  15 in total

1.  Anti-GD2 Strategy in the Treatment of Neuroblastoma.

Authors:  Richard K Yang; Paul M Sondel
Journal:  Drugs Future       Date:  2010       Impact factor: 0.148

2.  Serum levels of cytoplasmic melanoma-associated antigen at diagnosis may predict clinical relapse in neuroblastoma patients.

Authors:  Fabio Morandi; Maria Valeria Corrias; Isabella Levreri; Paola Scaruffi; Lizzia Raffaghello; Barbara Carlini; Paola Bocca; Ignazia Prigione; Sara Stigliani; Loredana Amoroso; Soldano Ferrone; Vito Pistoia
Journal:  Cancer Immunol Immunother       Date:  2011-06-10       Impact factor: 6.968

Review 3.  Antithetic roles of proteoglycans in cancer.

Authors:  Elena Garusi; Silvia Rossi; Roberto Perris
Journal:  Cell Mol Life Sci       Date:  2011-10-02       Impact factor: 9.261

4.  Melanoma cells treated with GGTI and IFN-gamma allow murine vaccination and enhance cytotoxic response against human melanoma cells.

Authors:  Guillaume Sarrabayrouse; Christine Pich; Raphaël Moriez; Virginie Armand-Labit; Philippe Rochaix; Gilles Favre; Anne-Françoise Tilkin-Mariamé
Journal:  PLoS One       Date:  2010-02-03       Impact factor: 3.240

Review 5.  Mimotope vaccination--from allergy to cancer.

Authors:  Regina Knittelfelder; Angelika B Riemer; Erika Jensen-Jarolim
Journal:  Expert Opin Biol Ther       Date:  2009-04       Impact factor: 4.388

6.  Chordoma and chondrosarcoma gene profile: implications for immunotherapy.

Authors:  Joseph H Schwab; Patrick J Boland; Narasimhan P Agaram; Nicholas D Socci; Tianhua Guo; Gary C O'Toole; Xinhui Wang; Elena Ostroumov; Christopher J Hunter; Joel A Block; Stephen Doty; Soldano Ferrone; John H Healey; Cristina R Antonescu
Journal:  Cancer Immunol Immunother       Date:  2008-07-19       Impact factor: 6.968

7.  CSPG4 as a prognostic biomarker in chordoma.

Authors:  Andrew J Schoenfeld; Xinhui Wang; Yangyang Wang; Francis J Hornicek; G Petur Nielsen; Zhenfeng Duan; Soldano Ferrone; Joseph H Schwab
Journal:  Spine J       Date:  2015-12-09       Impact factor: 4.166

8.  Multi-modality therapeutics with potent anti-tumor effects: photochemical internalization enhances delivery of the fusion toxin scFvMEL/rGel.

Authors:  Pål K Selbo; Michael G Rosenblum; Lawrence H Cheung; Wendy Zhang; Kristian Berg
Journal:  PLoS One       Date:  2009-08-19       Impact factor: 3.240

Review 9.  Mimotope vaccines: epitope mimics induce anti-cancer antibodies.

Authors:  Angelika B Riemer; Erika Jensen-Jarolim
Journal:  Immunol Lett       Date:  2007-08-22       Impact factor: 3.685

Review 10.  Theranostic impact of NG2/CSPG4 proteoglycan in cancer.

Authors:  Pier Andrea Nicolosi; Alice Dallatomasina; Roberto Perris
Journal:  Theranostics       Date:  2015-02-15       Impact factor: 11.556

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.